![]() | |
Clinical data | |
---|---|
Trade names | Trikafta and Kaftrio (with ivacaftor and tezacaftor) |
Other names | VX-445 |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a619061 |
License data |
|
Routes of administration | By mouth |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C26H34F3N7O4S |
Molar mass | 597.66 g·mol−1 |
3D model ( JSmol) | |
| |
|
Elexacaftor is a medication that acts as cystic fibrosis transmembrane conductance regulator (CFTR) corrector. [1]
It is available in a single pill with ivacaftor and tezacaftor; the fixed-dose combination, elexacaftor/tezacaftor/ivacaftor (brand name Trikafta), is used to treat people with cystic fibrosis who are homozygous for the f508del mutation. [1] [2] This combination was approved for medical use in the United States in 2019. [1] [3] [4]
The fixed-dose combination elexacaftor/tezacaftor/ivacaftor (Kaftrio) was approved for medical use in the European Union in August 2020, for the treatment of cystic fibrosis. [5] [6]
![]() | |
Clinical data | |
---|---|
Trade names | Trikafta and Kaftrio (with ivacaftor and tezacaftor) |
Other names | VX-445 |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a619061 |
License data |
|
Routes of administration | By mouth |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C26H34F3N7O4S |
Molar mass | 597.66 g·mol−1 |
3D model ( JSmol) | |
| |
|
Elexacaftor is a medication that acts as cystic fibrosis transmembrane conductance regulator (CFTR) corrector. [1]
It is available in a single pill with ivacaftor and tezacaftor; the fixed-dose combination, elexacaftor/tezacaftor/ivacaftor (brand name Trikafta), is used to treat people with cystic fibrosis who are homozygous for the f508del mutation. [1] [2] This combination was approved for medical use in the United States in 2019. [1] [3] [4]
The fixed-dose combination elexacaftor/tezacaftor/ivacaftor (Kaftrio) was approved for medical use in the European Union in August 2020, for the treatment of cystic fibrosis. [5] [6]